Texas Children’s Cancer Center is the country’s leader in the use of precision oncology strategies for the care of children with rare, relapsed, refractory and high-risk cancers – patients with limited treatment options who are most in need of novel therapeutic approaches.
Our precision oncology team applies state-of-the-art genomic testing to make the most informed decisions possible for the care of each child evaluated and treated at Texas Children’s Cancer Center.
Researchers in the Cancer Genetics and Genomics Program are leading cutting-edge studies to understand how genome sequencing can be used to implement more precisely-targeted patient-specific treatment plans and improve outcomes for childhood cancer patients.
Ranked #4 in the country by U.S. News & World Report.
We’re proud to be consistently named as a top program in Texas and the entire southwest region. Overall, Texas Children’s Hospital is ranked #4 and is on the Best Children’s Hospital Honor Roll for the ninth straight year.